Although overdose deaths from heroin and prescription opioids have declined, deaths involving synthetic opioids are on the rise. Much of the current wave of overdoses is linked to one synthetic opioid: fentanyl.
About half of all U.S. states now have policies that criminalize substance use during pregnancy, consider it grounds for civil commitment, or consider it child abuse or neglect. But research suggests that punitive policies aren't beneficial for infants or their mothers.
In this RAND Remote presentation, Beau Kilmer discusses how RAND is identifying and evaluating innovative approaches to tackle some of America's most pressing drug problems and help strengthen and safeguard communities.
While many illegally manufactured potent synthetic opioids (IMPSO) are produced in Asia, there is little evidence they have entered markets there. We consider the susceptibility to IMPSO's encroachment in markets in the Asia-Pacific region.
In this paper, we provide an overview of methodological challenges facing opioid policy researchers when conducting opioid policy evaluation studies using observational data, as well as some potential solutions to those challenges.
In the context of the pandemic, buprenorphine prescribers quickly transitioned to providing telemedicine visits in high volume; nonetheless, there are still many unknowns, including the quality and safety of widespread use of telemedicine for OUD treatment.
This study aimed to To quantify the availability of telehealth services at substance use treatment facilities in the U.S. at the beginning of the COVID-19 pandemic, and determine whether telehealth is available at facilities in counties with the greatest amount of social distancing. Relatively few substance use treatment facilities offered telehealth services at the onset of the COVID-19 pandemic. Policymakers and public health officials should do more to support facilities in offering telehealth services.
We conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine.
This study will evaluate whether the adapted intervention, also known as integrating support persons into recovery, is effective in increasing patient retention on buprenorphine when compared to usual care.
Although use of telemedicine for the treatment of opioid use disorders is growing, there is limited research on how it is actually being deployed in treatment. We explored how health centers across the U.S. are using it.
In this cross-sectional study with random assignment of clinicians and simulated-patient callers, many women, especially pregnant women, faced barriers to accessing treatment. Given the high out-of-pocket costs and lack of acceptance of insurance among many clinicians, access to affordable opioid use disorder treatment is a significant concern.
This cross-sectional study examines the number of patients prescribed buprenorphine by waivered-clinicians. Evidence shows waivered-clinicians who are able to prescribe buprenorphine treat fewer patients than their limit allows. With so much unmet demand for OUD treatment, this suggests the need for ongoing efforts to address treatment barriers.
We used insurance claims to examine the prevalence and prescribing patterns of prescription opioids in a national cohort of individuals experiencing a treated heroin-related overdose between 2010 and 2017.
Prescription opioid use and driving is a public health concern given the risks associated with drugged driving. We examined the prevalence and correlates of driving after taking prescription opioids among adults seeking emergency department treatment.
This article proceeds in three parts: discussions of the general goals and role of public health tort litigation, the demonstrated and potential value of opioid litigation to achieve public health goals, and a conclusion.
The existing literature on naloxone access laws in the United States supports beneficial effects for increased naloxone distribution, but provides inconclusive evidence for reduced fatal opioid overdose.